Egyptian Liver Journal

Table 1 Comparison of the baseline parameters in both groups

From: High efficacy of low-dose albumin infusion in the prevention of paracentesis-induced circulatory dysfunction

		Low-dose albumin	Standard-dose albumin	p
		N = 85	N = 25	p
Age (years)		53.19 ± 8.55	51.60 ± 6.84	0.397
Sex	Male	50 (58.8%)	9 (36%)	0.067
Sex	Female	35 (41.2%)	16 (64%)	0.067
Etiology	HCV	80 (93%)	22 (91.7%)	1
Etiology	Non-HCV	6 (7%)	2 (8.3%)	1
Child Pugh class	Child B	73 (85.9%)	13 (52%)	0.001
Child Pugh class	Child C	12 (14.1%)	12 (48%)	0.001
PICD	None	64 (75.3%)	22 (88%)	0.27
PICD	PICD	21 (24.7%)	3 (12%)	0.27
Weight, kg		90.56 ± 11.26	87.08 ± 14.18	0.252
MAP, mmHg		78.98 ± 6.40	77.58 ± 5.81	0.358
Heart rate, beat/minute		83.70 ± 13.73	83.12 ± 5.24	0.84
Paracentesis, L		9.78 ± 3.56	12.52 ± 3.60	0.001
Total bilirubin, mg/dL		3.04 ± 2.65	2.78 ± 1.59	0.643
Total protein, g/dL		6.38 ± 0.93	6.33 ± 1.21	0.836
Albumin, g/dL		2.20 ± 0.36	2.55 ± 0.60	0.002#
AST, U/L		53.48 ± 26.78	72.32 ± 48.92	0.106#
ALT, U/L		35.48 ± 27.80	35.84 ± 24.11	0.954
ALP, U/L		104.21 ± 132.88	119.24 ± 103.15	0.604
GGT, U/L		47.66 ± 46.11	52.95 ± 68.15	0.66
Hemoglobin, g/dL		10.36 ± 1.32	10.12 ± 1.98	0.319#
WBCs, 10⁹/L		6.90 ± 9.27	4.98 ± 2.55	0.309
Platelets, 10⁹/L		82.14 ± 33.32	83.60 ± 38.47	0.853
INR		1.62 ± 0.51	1.55 ± 0.28	0.495
Urea, mg/dL		55.35 ± 30.48	38.16 ± 17.07	0.003#
Creatinine, mg/dL		0.95 ± 0.27	0.85 ± 0.36	0.103#
Sodium, mmol/L		123.25 ± 13.85	128.16 ± 6.03	0.088
Potassium, mmol/L		4.28 ± 0.69	4.20 ± 0.58	0.636
Child Pugh score		10.36 ± 1.26	9.88 ± 1.56	0.113
MELD		15.24 ± 4.41	15.28 ± 4.11	0.964
MELD Na		22.88 ± 4.12	21.88 ± 4.02	0.285
PRA, pg/mL		859.62 ± 1151.34	165.93 ± 95.34	0.001#

PICD paracentesis-induced circulatory dysfunction, MAP mean arterial pressure, PRA plasma renin activity, HCV hepatitis C virus, MELD model for end-stage liver disease
^#Mann–Whitney U test

Back to article page